The global enteric disease testing market size was valued at USD 3.81 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 2.7% from 2023 to 2030. Vital drivers of this market include technological advancements and supportive government funding in emerging economies. Furthermore, growing global demand for early diagnostics is expected to enhance the applicability of the market, fueling its growth.
Throughout the COVID-19 pandemic, there was an increasing focus on viral and bacterial infections, leading individuals to prioritize the consumption of home-cooked and hygienic food to minimize the risk of infection. Therefore, there was a decrease in the incidence of enteric diseases and a subsequent decline in the demand for enteric disease testing in 2020 and 2021. Additionally, COVID-19 testing had top priority during the pandemic, surpassing testing for other infectious diseases, due to which the demand for enteric disease testing products experienced a negative impact, thereby impeding market growth.
In regions such as Asia, Africa, and Latin America, the prevalence of enteric infections, including salmonella, campylobacter, escherichia coli, and norovirus, remains significantly high. According to the National Library of Medicine, as of 2018, a case fatality rate of 1% is observed in enteric fever cases in the Asia and Africa regions. Consequently, there is an increasing demand for enteric disease testing to enable accurate and timely diagnoses. Moreover, there is increasing awareness among individuals, healthcare providers, and government entities regarding the importance of early detection and effective management of enteric diseases. As a result, various organizations and government bodies are undertaking initiatives to enhance awareness, implement screening programs, and advocate for the utilization of diagnostic tests, thereby stimulating market growth.
The traditional diagnostic process of enteric diseases was based on the culture method which demanded skilled staff and was a time-consuming procedure. The development of molecular diagnostics and other diagnostic technologies revolutionized the enteric disease testing market over the last decade. The increasing mortality rate due to these conditions and the cost efficiency of technologically advanced diagnostic systems are expected to drive the demand for early diagnosis of these conditions.
Initial symptoms associated with enteric diseases include abdominal cramps, vomiting, nausea, and anorexia, which can progress to severe conditions characterized by substantial fluid and nutrient loss from the body. The vulnerability of pediatric and geriatric age groups to these diseases is sensitive due to their weakened immune systems. According to the Bill and Melinda Gates Foundation, annually, approximately 500,000 young children under the age of 5 succumb to enteric and diarrheal diseases, predominantly in developing nations. Furthermore, an estimated 25,000 children annually lose their lives to enteric fever, primarily affecting regions lacking access to safe water and adequate sanitation facilities.
The mild initial symptoms of enteric diseases are sometimes overlooked, which poses a significant constraint to the market. These diseases have emerged as a leading cause of morbidity and mortality globally, particularly in developing countries with inadequate drainage and sanitation infrastructure. In terms of incidence and epidemiology, it is estimated that developing nations contribute to more than 85% of the total enteric infection cases.
Rising incidence of enteric diseases and the cost-efficiency of technologically advanced diagnostic systems are expected to drive demand for the early diagnosis of enteric disease. For instance, according to the Centers for Disease Control and Prevention, salmonella bacteria cause approximately 1.35 million infections, around 26,500 hospitalizations, and about 420 deaths every year in the U.S. Increasing incidence of enteric conditions in developing economies along with a lack of adequate laboratory settings and limited awareness is expected to provide a largely untapped market. According to the Foundation Merieux, enteric diseases are the second leading cause of death among children under 5 years in Asian and African countries. In addition, 90% of deaths caused by diarrhea are due to a lack of access to safe drinking water and basic sanitation facilities. Furthermore, 90% of deaths due to typhoid occur in Asia. As of 2021, there are an estimated 11 to 21 million typhoid fever cases and 128,000 to 161,000 deaths in south Asian countries every year. Thus, the increasing prevalence of enteric disease and poor sanitation facilities in developing countries provides a largely untapped market.
Molecular diagnostics are used in various areas of microbiology, which include strain identification and isolation of enteric pathogens. Disease-causing microorganisms are also studied using different molecular diagnostics techniques. The application of molecular diagnostics in microbiology is expected to increase due to the introduction of technologically advanced instruments with improved accuracy levels. Clinical laboratories are adopting molecular diagnostics as a part of laboratory automation. Currently, polymerase chain reaction (PCR), implicit association test (IAT), and gene chip are the most widely used molecular diagnostic tests for infectious diseases. Thus, the rising adoption of molecular diagnostics in the detection of enteric diseases is expected to drive the enteric diseases market over the forecast period.
Technological advancement is another key factor accelerating market growth. Technological advancements such as gastrointestinal panel tests are used for the identification and qualitative detection of multiple parasitic, bacterial, and viral nucleic acids in individuals with signs and symptoms of gastroenteritis or infectious colitis. The tests are performed on saliva and stool samples to generate rapid results for 15 pathogens in 6 hours. It is also used for testing the inherited food sensitivities/allergies to organisms such as Toxoplasma gondii and Entamoeba histolytica. This test has been approved by the U.S. FDA. Market players undergoing clinical studies to develop a new diagnostic test with high accuracy and high-performance delivery is anticipated to drive the market. For instance,in November 2019, the XTAG Gastrointestinal (GPP) test was approved by the Food and Drug Administration (FDA). XTAG is a multiplexed nucleic acid test designed to detect multiple viral, parasitic, and bacterial nuclei in stool samples simultaneously.
Based on disease type the market of enteric disease testing is segmented into bacterial, viral, and parasitic enteric diseases. The bacterial enteric diseases segment dominated the market with the largest revenue share and is also expected to grow at the fastest CAGR during the forecast period from 2023 to 2030. Various bacteria that cause these diseases include C. difficile, E. coli, shigella, salmonella, and campylobacter. According to the National Institute of Health, C. Difficile infections affect about half a million people in the U.S. every year. About 29,000 of these people die within a month of being diagnosed with the disease and E. Coli causes approximately 63,000 cases of hemorrhagic colitis in the U.S. every year. The parasitic disease testing segment is expected to witness significant growth owing to rising incidences of such infections and the emergence of new parasitic strains. According to the World Health Organization (WHO), as of February 2023, at least 18 countries are still reporting cholera outbreaks. The mortality from these outbreaks is alarming since many countries have reported higher cholera mortality rates than in the past years. The global cholera mortality rate in 2021 was around 1.9%, and similar trends are expected for 2022 and 2023.
According to the Child Health Epidemiology Research Group (CHERG), enteric pathogens such as salmonella spp., rotavirus, and V. cholera caused more mortality as compared to other enteric pathogens and thus the WHO committee has given the highest priority to the development of new and improved vaccines against these pathogens. Even if some viruses are geographically ubiquitous, such as rotavirus, which infects about 90 percent of the population of the world younger than five years of age, most of the time infections are environmentally determined along with restricted seasonal and geographical patterns that are related to hygiene and degree of sanitation and access to clean drinking water.
Europe dominated the market with the largest revenue share of 39.0% in 2022. Germany holds a considerable share in Europe’s market, primarily owing to its large geriatric population. According to the United Nation’s population data, one in every 20 people in Germany is aged above 80, which is expected to increase to one in every 6 individuals by 2050. People above the age of 65 accounted for 22.4% of the total population. In 2019, there were 90.4 million people above 65 years of age living in Europe. Problems with the increasing geriatric population include a higher risk of enteric diseases due to the onset of senescence & decreased immunity levels. Rapid diagnostic techniques such as point-of-care diagnostic devices are useful for this demographic. Key manufacturers such as Roche and Bio-Rad are strengthening their operations in Germany, which is expected to boost the enteric disease testing market.
Asia Pacific is expected to grow at the fastest CAGR of 4.0% over the forecast period from 2023 to 2030 owing to rising awareness levels among people for testing and increasing infections. Attractive regions for the market are placed in developing nations such as China and India thereby promoting the fastest growth for Asia Pacific. The spread of enteric diseases is higher in Asian countries. For instance, Bangladesh reports the highest number of typhoid cases 252 cases per 100,000.
Brazil is expected to hold strong opportunities for market growth. Growth in economic & political stability has led to positive economic growth in Brazil. Healthcare reforms, such as the Unified Health System (SUS), provide free healthcare services to individuals at all levels without charging an additional amount. The SUS is a combination of public, private, and supplemental healthcare services. Supportive government initiatives, such as collaboration between the U.S. and Brazil on biomedical research to accelerate R&D in the diagnosis & treatment of infectious diseases, are also boosting the market. However, access to advanced diagnostics in Brazil is currently limited to urban areas due to the lack of infrastructure in rural settings which could slow down the market growth.
The players are involved in technological advancement and new product development in order to sustain their position in the market and offer cost-efficient solutions. For instance, in May 2022, BD announced the launch of a fully automated, ultra-high-throughput molecular diagnostic platform for infectious diseases in the U.S. Additionally, in February 2021, Thermo Fisher Scientific, Inc. announced the acquisition of Mesa Biotech, which aims to expand the benefits of molecular diagnostics at the point of care.
Furthermore, In January 2019, DiaSorin S.p.A. announced the launch of the FDA-approved Calprotectin test, LIAISON, for quantitative calprotectin assays in stool samples. This comes on the heels of the recent strategic partnership announced by DiaSorin S.p.A. with Meridian Bioscience to sell a stool antigen test. The following are some of the major participants in the global enteric disease testing market:
Bio-Rad Laboratories, Inc.
Quest Diagnostics Incorporated
Market size value in 2023
USD 3.89 billion
Revenue forecast in 2030
USD 4.68 billion
CAGR of 2.7% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Disease type, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa ;UAE; Kuwait
Key companies profiled
Abbott; BD; Biomerica; BIOMÉRIEUX; Bio-Rad Laboratories, Inc.; Cepheid; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience; Quest Diagnostics Incorporated
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global enteric disease testing market report based on disease type, and region:
Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
Bacterial Enteric Disease
Viral Enteric Disease
Parasitic Enteric Disease
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
b. The global enteric disease testing market size was estimated at USD 3.81 billion in 2022 and is expected to reach USD 3.89 billion in 2023.
b. The global enteric disease testing market is expected to grow at a compound annual growth rate of 2.7% from 2023 to 2030 to reach USD 4.68 billion by 2030.
b. North America dominated the enteric disease testing market with a share of 38.1% in 2022. This is attributable to the high prevalence of food and waterborne infections.
b. Some key players operating in the enteric disease testing market include Abbott, Bio Rad Laboratories, Quest Diagnostics, Becton Dickinson and Company, Cepheid, DiaSorin, Meridian BioSciences, and Coris BioConcept.
b. Key factors that are driving the enteric disease testing market growth include technological advancements, supportive government funding in emerging economies, and growing global demand for early diagnosis.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."